Published in JAMA Health Forum · View the paper (DOI)
The GLP-1 RA market experienced a surge in demand following the semaglutide and tirzepatide shortages. Compounded GLP-1 RAs sourced from unlicensed facilities pose clinical and regulatory challenges.
Coverage from 2 institutions